GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Cash-to-Debt

Vectus Biosystems (ASX:VBS) Cash-to-Debt

: No Debt (1) (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vectus Biosystems's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vectus Biosystems could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Vectus Biosystems's Cash-to-Debt or its related term are showing as below:

ASX:VBS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 0.91   Max: No Debt
Current: 28.84

During the past 8 years, Vectus Biosystems's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 0.91.

ASX:VBS's Cash-to-Debt is ranked better than
68.1% of 1539 companies
in the Biotechnology industry
Industry Median: 6.74 vs ASX:VBS: 28.84

Vectus Biosystems Cash-to-Debt Historical Data

The historical data trend for Vectus Biosystems's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash-to-Debt
Premium Member Only Premium Member Only Premium Member Only 0.02 0.38 0.75 0.21 42.16

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.21 No Debt 42.16 No Debt

Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Cash-to-Debt falls into.



Vectus Biosystems Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vectus Biosystems's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Vectus Biosystems's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Vectus Biosystems had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Vectus Biosystems Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines